The Fraunhofer-Gesellschaft, on behalf of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, has signed an asset transfer agreement with Takeda GmbH to exclusively transfer its Surfactant and Continuous Powder Aerosolization (CPA) program assets to Fraunhofer ITEM.
The transfer includes the CPA technology for continuous aerosolization of powdery substances and the know-how to manufacture recombinant surfactant protein C, together with the associated intellectual property. The Fraunhofer ITEM is thus in a position to continue the development of therapies involving continuous inhalation various medications, begun 10 years ago.
Closing down its respiratory department, Takeda transferred its Surfactant and CPA program assets to Fraunhofer ITEM including the associated intellectual property. The CPA technology is the first non-invasive administration method for powdery surfactant drugs.
Surfactant drugs have to be administered to patients with surfactant deficiency, which is common, for example, in preterm in neonates. Furthermore, this therapeutic approach has been investigated in other acute and chronic life-threatening diseases such as acute lung injury and COPD.
Surfactant (“surface-active agent“) is secreted by certain lung cells und reduces surface tension in the alveoli, thereby preventing their collapse. Physical activity causes an increase, smoking a decrease in surfactant production. Fetal surfactant production starts in week 24 of gestation. Preterm neonates, in particular if born before week 34 of gestation, suffer from varying degrees of pulmonary surfactant deficiency, which may lead to neonate respiratory distress syndrome.
Surfactant-based therapy is the standard of care. Its use is limited, however, due to the currently invasive administration methodology. The CPA technology simplifies surfactant delivery to neonates and can also be used for children and adults. Recombinant surfactant protein C is the first recombinant surfactant protein suitable for use in synthetic surfactant drugs.
CPA is also a suitable technology to continuously deliver pulmonary high doses of non-soluble drugs to patients. In respiratory care, the standard of aerosolization for continuous inhalation is currently confined to different classes of nebulizers. In contrast, the CPA technology for the first time enables continuous inhaled administration of non-soluble drugs. In addition, it delivers a higher drug concentration to patients and enables a higher lung deposition rate.
Dr. Gerhard Pohlmann, Head of Medical Inhalation Technology at Fraunhofer ITEM with a 10+ year track record in CPA technology development, said: “As a long-standing partner in the CPA program, Fraunhofer ITEM is delighted to continue development of the surfactant and CPA technology platform. We are currently in the strategic process of reorganizing the program and selecting development partners.”
Dr. Gerhard Pohlmann; +49 511 5350-116
Dr. Cathrin Nastevska; +49 511 5350-225
The text of this press release can be found on our homepage at
Dr. Cathrin Nastevska | Fraunhofer Institute for Toxicology and Experimental Medicine
Skin patch dissolves 'love handles' in mice
18.09.2017 | Columbia University Medical Center
Medicine of the future: New microchip technology could be used to track 'smart pills'
13.09.2017 | California Institute of Technology
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.
Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
19.09.2017 | Event News
19.09.2017 | Physics and Astronomy
19.09.2017 | Power and Electrical Engineering